AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28319270 — intervention group
Group type: EXPERIMENTAL
Intervention: PFD patch
Number of subjects: 30
Study 28319270 — intervention group
Group type: COMPARATOR
Intervention: Laser alone
Number of subjects: 30
Study 26044495 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (multi-component antenatal vaccine promotion package)
Number of subjects: 325
Study 26044495 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 325
Study 23473784 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain patients receiving opioids
Number of subjects: 0
Study 23473784 — intervention group
Group type: COMPARATOR
Intervention: Chronic pain patients off opioid treatment
Number of subjects: 0
Study 23473784 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain patients (generalized and neuropathic pain)
Number of subjects: 0
Study 23473784 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain patients (localized pain)
Number of subjects: 0
Study 23473784 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain patients (overall)
Number of subjects: 0
Study 20374275 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (L-AMB) 3 mg/kg QD for 14 days followed by L-AMB 3 mg/kg QD
Number of subjects: 91
Study 20374275 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (L-AMB) 10 mg/kg QD for 14 days followed by L-AMB 3 mg/kg QD
Number of subjects: 91
Study 18245686 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12 percent chlorhexidine lavage during ultrasonic scaling and use of chlorhexidine mouthrinse at home
Number of subjects: 140
Study 18245686 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 140
Study 17228674 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulge group (n=11)
Number of subjects: 30
Study 17228674 — intervention group
Group type: EXPERIMENTAL
Intervention: Protrusion group (n=9)
Number of subjects: 30
Study 17228674 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolapsus group (n=10)
Number of subjects: 30
Study 17228674 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=9)
Number of subjects: 30
Study 14623654 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K supplementation
Number of subjects: 115
Study 14623654 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen supplementation
Number of subjects: 115
Study 14623654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 10817026 — intervention group
Group type: EXPERIMENTAL
Intervention: FES-biofeedback
Number of subjects: 90
Study 10817026 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive PFM exercise
Number of subjects: 90
Study 10817026 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study 8888415 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (performed 175 trials on acquisition day)
Number of subjects: 61
Study 8888415 — intervention group
Group type: COMPARATOR
Intervention: Control group (performed 10 trials, sat quietly for 155 trials, then performed 10 more trials)
Number of subjects: 61
Study 8888415 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (performed 20 trials on retention day)
Number of subjects: 61
Study 8888415 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (EEG data analysis)
Number of subjects: 61
Study 8888415 — intervention group
Group type: COMPARATOR
Intervention: Control group (EEG data analysis)
Number of subjects: 61
Study 1894676 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm gauntlet (Colles') cast, leaving the thumb free
Number of subjects: 392
Study 1894676 — intervention group
Group type: COMPARATOR
Intervention: Conventional 'scaphoid' plaster incorporating the thumb
Number of subjects: 392
Study 7299342 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised intervention (advice on diet, cigarette smoking, and physical activity)
Number of subjects: 3336
Study 7299342 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 3336
Study 31782589 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin
Number of subjects: 0
Study 31782589 — intervention group
Group type: COMPARATOR
Intervention: Treatment of physician's choice (TPC)
Number of subjects: 0
Study 31132055 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized visual objects with consistent temporal presentation
Number of subjects: 0
Study 31132055 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized visual objects with inconsistent temporal presentation (or jitter)
Number of subjects: 0
Study 31132055 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual motion via a radial field of coherent central dot motion without jitter
Number of subjects: 0
Study 31132055 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual motion via a radial field of coherent central dot motion with jitter
Number of subjects: 0
Study 28818518 — intervention group
Group type: EXPERIMENTAL
Intervention: Seladelpar 50 mg/day
Number of subjects: 41
Study 28818518 — intervention group
Group type: EXPERIMENTAL
Intervention: Seladelpar 200 mg/day
Number of subjects: 41
Study 28818518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 25782032 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin patch
Number of subjects: 576
Study 25782032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 576
Study 23855449 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion intervention (10-week duration)
Number of subjects: 324
Study 21314695 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5-hour alcohol training program
Number of subjects: 395
Study 21314695 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 395
Study 19601704 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine ER
Number of subjects: 411
Study 19601704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 411
Study 17530980 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity power training
Number of subjects: 0
Study 17530980 — intervention group
Group type: COMPARATOR
Intervention: Traditional resistance training
Number of subjects: 0
Study 15303242 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 75 mg to 225 mg/day
Number of subjects: 434
Study 15303242 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg to 50 mg/day
Number of subjects: 434
Study 15303242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 434
Study 11834153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive care therapy (ICT) in neurosurgical intensive care unit for the first 2 weeks after admission
Number of subjects: 200
Study 11834153 — intervention group
Group type: COMPARATOR
Intervention: Conventional care therapy (CCT) in ordinary ward
Number of subjects: 200
Study 11834153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive care therapy (ICT) for patients under 50 years
Number of subjects: 200
Study 11834153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive care therapy (ICT) for patients with GCS 6-8 on admission
Number of subjects: 200
Study 11834153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive care therapy (ICT) for patients with brain stem injury below mesencephalon
Number of subjects: 200
Study 11834153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive care therapy (ICT) for patients undergoing conservative therapy only
Number of subjects: 200
Study 9647379 — intervention group
Group type: EXPERIMENTAL
Intervention: New covered needle catheter (Clisco needle)
Number of subjects: 10
Study 9647379 — intervention group
Group type: COMPARATOR
Intervention: Ordinary disposable needles
Number of subjects: 10
Study 7864619 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunch with 431 kcal (low-fat, low-CHO)
Number of subjects: 12
Study 7864619 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunch with 844 kcal (high-fat, high-CHO)
Number of subjects: 12
Study 7864619 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast, lunch, and afternoon snack totaling approximately 700 kcal (low)
Number of subjects: 12
Study 7864619 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast, lunch, and afternoon snack totaling approximately 1200 kcal (medium)
Number of subjects: 12
Study 7864619 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast, lunch, and afternoon snack totaling approximately 1700 kcal (high)
Number of subjects: 12
Study 2680964 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Number of subjects: 45
Study 2680964 — intervention group
Group type: COMPARATOR
Intervention: Regular coffee
Number of subjects: 45
Study 938849 — intervention group
Group type: EXPERIMENTAL
Intervention: Sialography
Number of subjects: 169
Study 938849 — intervention group
Group type: COMPARATOR
Intervention: Scintigraphy
Number of subjects: 169
Study 31625293 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarpogrelate
Number of subjects: 74
Study 31625293 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 74
Study 28584072 — intervention group
Group type: EXPERIMENTAL
Intervention: Publication of the 2009 Appropriate Use Criteria (AUC) for myocardial perfusion imaging (MPI)
Number of subjects: 3072611
Study 28584072 — intervention group
Group type: COMPARATOR
Intervention: Period from January 2000 to October 2005
Number of subjects: 3072611
Study 28584072 — intervention group
Group type: COMPARATOR
Intervention: Period from November 2005 to June 2009
Number of subjects: 3072611
Study 28584072 — intervention group
Group type: COMPARATOR
Intervention: Period from March 2014 to December 2015
Number of subjects: 3072611
Study 25465508 — intervention group
Group type: EXPERIMENTAL
Intervention: Horse Riding Simulation (HRS) exercise for 20 min, 5 times a week, for 8 weeks
Number of subjects: 30
Study 25465508 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 30
Study 25465508 — intervention group
Group type: EXPERIMENTAL
Intervention: Horse Riding Simulation (HRS) exercise
Number of subjects: 30
Study 23796204 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab 250 mg/m²
Number of subjects: 39
Study 23796204 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab 250 mg/m² with paclitaxel 80 mg/m²
Number of subjects: 39
Study 21763419 — intervention group
Group type: COMPARATOR
Intervention: Inspired oxygen concentration of 30%
Number of subjects: 45
Study 21763419 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspired oxygen concentration of 50%
Number of subjects: 45
Study 21763419 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspired oxygen concentration of 80%
Number of subjects: 45
Study 21763419 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 45
Study 21763419 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin
Number of subjects: 45
Study 19406871 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 8 mg/day
Number of subjects: 1252
Study 19406871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1252
Study 17952841 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO)
Number of subjects: 125
Study 17952841 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone + Simvastatin (PIO+SIMVA)
Number of subjects: 125
Study 17952841 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (SIMVA)
Number of subjects: 125
Study 15302980 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine retard
Number of subjects: 199
Study 15302980 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitor
Number of subjects: 199
Study 11149479 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumping intervention (100, two-footed jumps off 61-cm boxes, three times per week for 7 months)
Number of subjects: 89
Study 11149479 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonimpact stretching exercises, three times per week for 7 months)
Number of subjects: 89
Study 11149479 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumping intervention
Number of subjects: 89
Study 9482764 — intervention group
Group type: EXPERIMENTAL
Intervention: OKG bolus (23.7 +/- 2.1 d)
Number of subjects: 54
Study 9482764 — intervention group
Group type: EXPERIMENTAL
Intervention: OKG administration
Number of subjects: 54
Study 9482764 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g OKG/d
Number of subjects: 54
Study 9482764 — intervention group
Group type: COMPARATOR
Intervention: OKG (10, 20, or 30 g/d)
Number of subjects: 54
Study 7744131 — intervention group
Group type: EXPERIMENTAL
Intervention: nimesulide 200mg/day
Number of subjects: 200
Study 7744131 — intervention group
Group type: COMPARATOR
Intervention: etodolac 600mg/day
Number of subjects: 200
Study 2910989 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol administration (0.1 mg/kg iv)
Number of subjects: 45
Study 2910989 — intervention group
Group type: COMPARATOR
Intervention: Active standing
Number of subjects: 45
Study 972268 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin and Tobramycin (80 mg intravenous injection)
Number of subjects: 6
Study 31161661 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive group
Number of subjects: 201
Study 29752265 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic transcriptional reporter designed for PhoB activity, utilizing both stable and destabilized variants of green fluorescent protein (GFP).
Number of subjects: 83
Study 29752265 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic transcriptional reporter in different members of the Proteobacteria.
Number of subjects: 83
Study 26683756 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (5 mcg twice daily for 1 month, then 10 mcg twice daily for 2 months)
Number of subjects: 32
Study 26683756 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 32
Study 24292873 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic noninvasive ventilation (NIV), applied intermittently during 6 h per day for 48 h following surgery
Number of subjects: 360
Study 24292873 — intervention group
Group type: COMPARATOR
Intervention: Conventional postoperative treatment without NIV
Number of subjects: 360
Study 23031322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IIT) guided by real-time continuous glucose monitoring (CGM), n = 63
Number of subjects: 174
Study 23031322 — intervention group
Group type: COMPARATOR
Intervention: Algorithm guided by selective arterial blood glucose measurements with simultaneously blinded CGM for 72 hours, n = 111
Number of subjects: 174
Study 21060042 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser flap creation
Number of subjects: 21
Study 21060042 — intervention group
Group type: COMPARATOR
Intervention: Mechanical microkeratome flap creation
Number of subjects: 21
Study 17595417 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 32
Study 17595417 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Training (FT)
Number of subjects: 32
Study 17595417 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional plus Resistance Training (FRT)
Number of subjects: 32
Study 17595417 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 32
Study 17595417 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking Speed
Number of subjects: 32
Study 17595417 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-leg Balance
Number of subjects: 32
Study 17595417 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Composition
Number of subjects: 32
Study 16213340 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal jugular vein (IJV) catheterization
Number of subjects: 45
Study 16213340 — intervention group
Group type: COMPARATOR
Intervention: Subclavian vein (SV) catheterization
Number of subjects: 45
Study 12399793 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (0.1 mg/kg)
Number of subjects: 46
Study 12399793 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.033 mg/kg)
Number of subjects: 46
Study 12399793 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 46
Study 12399793 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 46
Study 12399793 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate and Midazolam
Number of subjects: 46
Study 10460116 — intervention group
Group type: EXPERIMENTAL
Intervention: Supple elastic TE orthosis
Number of subjects: 10
Study 10460116 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-rigid TE orthosis
Number of subjects: 10
Study 10460116 — intervention group
Group type: COMPARATOR
Intervention: All three types of TE orthoses
Number of subjects: 10
Study 10460116 — intervention group
Group type: EXPERIMENTAL
Intervention: TE orthoses (general)
Number of subjects: 10
Study 10460116 — intervention group
Group type: EXPERIMENTAL
Intervention: Supple elastic orthosis
Number of subjects: 10
Study 10460116 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-rigid orthosis
Number of subjects: 10
Study 7497502 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial stenting (Group A)
Number of subjects: 60
Study 7497502 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral stenting (Group B)
Number of subjects: 60
Study 2699986 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dialysate flow rate
Number of subjects: 24
Study 2699986 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 liter exchange volume
Number of subjects: 24
Study 961545 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper bracelets
Number of subjects: 300
Study 961545 — intervention group
Group type: COMPARATOR
Intervention: Placebo bracelets (amodised aluminum resembling copper)
Number of subjects: 300
Study 961545 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper bracelet worn around the wrist
Number of subjects: 300
Study 31180234 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate Nostril Breathing (ANB)
Number of subjects: 11
Study 31180234 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot Reflexology (FR)
Number of subjects: 11
Study 28661758 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day)
Number of subjects: 3823
Study 28661758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3823
Study 28661758 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 3823
Study 28661758 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 3823
Study 25659070 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic infiltration and standard care
Number of subjects: 638
Study 25659070 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 638
Study 23700057 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 15 marrow response
Number of subjects: 0
Study 23700057 — intervention group
Group type: COMPARATOR
Intervention: Prednisone response
Number of subjects: 0
Study 21830944 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide (PEA)
Number of subjects: 15
Study 21830944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 18678568 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional thumb orthosis used daily
Number of subjects: 40
Study 18678568 — intervention group
Group type: COMPARATOR
Intervention: Control group (orthosis used only during evaluation)
Number of subjects: 40
Study 16863699 — intervention group
Group type: EXPERIMENTAL
Intervention: Active trigger points in ETTH patients
Number of subjects: 10
Study 16863699 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent trigger points in ETTH patients
Number of subjects: 10
Study 16863699 — intervention group
Group type: COMPARATOR
Intervention: Latent trigger points in control subjects
Number of subjects: 10
Study 16863699 — intervention group
Group type: COMPARATOR
Intervention: Comparison of active TrPs between ETTH patients and controls
Number of subjects: 10
Study 12582219 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (30 mg for 24 hours)
Number of subjects: 12
Study 12582219 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (100 mg for 24 hours)
Number of subjects: 12
Study 12582219 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (300 mg/24 hours with food)
Number of subjects: 12
Study 12582219 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (300 mg/24 hours fasting)
Number of subjects: 12
Study 12582219 — intervention group
Group type: COMPARATOR
Intervention: Placebo (with food)
Number of subjects: 12
Study 11054441 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 54 mg/m(2) and Carboplatin AUC 6 mg.min/mL
Number of subjects: 58
Study 11054441 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 67.5 mg/m(2) and Carboplatin AUC 6 mg.min/mL
Number of subjects: 58
Study 11054441 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 81 mg/m(2) and Carboplatin AUC 6 mg/mL
Number of subjects: 58
Study 11054441 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 54.5 mg/m(2) to 94.5 mg/m(2)
Number of subjects: 58
Study 9085389 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment at points previously used for anti-smoking (test group, TG)
Number of subjects: 46
Study 9085389 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture treatment at points assumed to have no effect for smoking cessation (control group, CG)
Number of subjects: 46
Study 8210832 — intervention group
Group type: EXPERIMENTAL
Intervention: Post myocardial infarction survival trial
Number of subjects: 0
Study 8210832 — intervention group
Group type: COMPARATOR
Intervention: Multicentre heart failure study
Number of subjects: 0
Study 3546149 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 200 mg b.i.d. by oral route
Number of subjects: 1436
Study 3546149 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 300 mg b.i.d. by oral route
Number of subjects: 1436
Study 3546149 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg b.i.d. by oral route
Number of subjects: 1436
Study 3546149 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (all dosages combined)
Number of subjects: 1436
Study 31453531 — intervention group
Group type: EXPERIMENTAL
Intervention: SPRI-P (pool-based intervention)
Number of subjects: 73